Advertisement
YOU ARE HERE: LAT HomeCollectionsVirazole Drug
IN THE NEWS

Virazole Drug

FEATURED ARTICLES
BUSINESS
February 18, 1995 | GREG JOHNSON, TIMES STAFF WRITER
Shares of ICN Pharmaceuticals Inc. fell 23% in heavy New York Stock Exchange trading Friday after the company said the U.S. Food and Drug Administration would not approve its Virazole drug as a treatment for hepatitis C. The Costa Mesa-based company's stock price fell $5.25 to $17.38. Trading topped 1.99 million shares, nearly 10 times the issue's three-month daily average of 205,600. ICN was Friday's biggest percentage loser in NYSE trading.
ARTICLES BY DATE
BUSINESS
July 25, 1997 | JAMES S. GRANELLI, TIMES STAFF WRITER
ICN Pharmaceuticals Inc. said Thursday that it has agreed to pay $15 million to settle a lawsuit that accused its chairman of insider trading and the company of misleading investors about its prize drug, Virazole. The Costa Mesa drug maker and its chairman, Milan Panic, will pay about $12 million to end the 2-year-old lawsuit and the company's insurer will pay the rest, according to two individuals familiar with the terms.
Advertisement
BUSINESS
June 2, 1994 | Anne Michaud, Times staff writer
SPI Turns to PR: SPI Pharmaceuticals in Costa Mesa said Wednesday it has hired public relations agency Edelman Medical Communications of New York to give its products higher visibility in the scientific community. In particular, SPI said, it wants to promote its leading drug, Virazole.
BUSINESS
August 15, 1996 | BARBARA MARSH
A Canadian federal appeals court threw out a claim by ICN Pharmaceuticals Inc. that challenged a government agency's jurisdiction over the drug company's prices for its main drug, Virazole. Two weeks ago, the Canadian agency, the Patented Medicine Prices Review Board, ordered the drug company to pay a fine and penalties totaling $1.8 million for "excessively" overcharging hospitals for the drug.
BUSINESS
December 6, 1994 | GREG JOHNSON, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock tumbled 13% Monday after the U.S. Food and Drug Administration ordered the company to resubmit an application for a key antiviral drug it has developed. ICN, based in Costa Mesa, sought regulatory approval in June to use its drug Virazole as a stand-alone treatment for hepatitis C. On Monday, however, the company said it will probably seek approval for use of Virazole in combination with other drugs.
BUSINESS
July 11, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Virazole has been the wonder drug for ICN Pharmaceuticals Inc., but shareholders simply wonder if it's ever going to be approved in the United States to combat any major illness. Over the years, ICN stock has risen and fallen on news that Virazole was being tested or wasn't being approved as a treatment for AIDS or the highly contagious hepatitis C liver ailment.
BUSINESS
April 30, 1992
Yugoslav health officials have given approval for SPI Pharmaceutical Inc.'s Belgrade subsidiary to market its patented antiviral drug, Virazole, for injection treatment of a deadly fever, the company said Wednesday. Yugoslavia is the first European nation to authorize use of Virazole to treat hemorrhagic fever associated with Renal Syndrome. The disease is characterized by severe shock, internal bleeding and kidney failure and is caused by the Hantaan virus.
BUSINESS
March 12, 1993 | James M. Gomez / Times staff writer
SPI Pharmaceutical Inc.'s drug Virazole is spreading like the flu. The Costa Mesa drug manufacturer announced this week that it has received final approval to sell the drug in Luxembourg. Virazole, an anti-virus drug, will be used by doctors in that European country in aerosol form to treat patients with influenza A and B infections. Symptoms of those flu viruses include fever, shivering, aching limbs, headache, sore throat and a persistent dry cough.
BUSINESS
August 14, 1991 | From Times Staff and Wire Reports
ICN Seeks OK for New Use of Antiviral Drug: ICN Pharmaceuticals Inc. of Costa Mesa has applied to the Food and Drug Administration for permission to use the drug Virazole to combat the Hantaan virus, which can cause kidney failure in humans. The rodent-borne disease is uncommon in the United States, but affects about 350,000 people each year, mostly in poorer countries, said Jack Sholl, an ICN spokesman. It is fatal in about 18% to 35% of the cases.
BUSINESS
July 11, 1996 | BARBARA MARSH, TIMES STAFF WRITER
Virazole has been the wonder drug for ICN Pharmaceuticals Inc., but shareholders simply wonder if it's ever going to be approved in the United States to combat any major illness. Over the years, ICN stock has risen and fallen on news that Virazole was being tested or wasn't being approved as a treatment for AIDS or the highly contagious hepatitis C liver ailment.
BUSINESS
February 25, 1995 | JAMES S. GRANELLI, TIMES STAFF WRITER
The chairman of ICN Pharmaceuticals Inc., pressed by the company's fast-falling stock price and the disclosure of his own questionable stock deals, said Friday that he wants the ICN board to set up a committee "as soon as possible" to investigate the latest developments.
BUSINESS
February 23, 1995 | HOPE HAMASHIGE, SPECIAL TO THE TIMES
An angry shareholder has sued ICN Pharmaceuticals Inc., alleging that the company withheld information that its drug, Virazole, was rejected by the Food and Drug Administration last fall as a treatment for hepatitis C. Additionally, the suit accuses company Chairman Milan Panic of profiting by selling a portion of his ICN stock in the months between the time the company was notified of the government's rejection and when it released that information to the public.
BUSINESS
February 18, 1995 | GREG JOHNSON, TIMES STAFF WRITER
Shares of ICN Pharmaceuticals Inc. fell 23% in heavy New York Stock Exchange trading Friday after the company said the U.S. Food and Drug Administration would not approve its Virazole drug as a treatment for hepatitis C. The Costa Mesa-based company's stock price fell $5.25 to $17.38. Trading topped 1.99 million shares, nearly 10 times the issue's three-month daily average of 205,600. ICN was Friday's biggest percentage loser in NYSE trading.
BUSINESS
December 6, 1994 | GREG JOHNSON, TIMES STAFF WRITER
ICN Pharmaceuticals Inc.'s stock tumbled 13% Monday after the U.S. Food and Drug Administration ordered the company to resubmit an application for a key antiviral drug it has developed. ICN, based in Costa Mesa, sought regulatory approval in June to use its drug Virazole as a stand-alone treatment for hepatitis C. On Monday, however, the company said it will probably seek approval for use of Virazole in combination with other drugs.
BUSINESS
October 31, 1991 | ANNE MICHAUD
ICN Pharmaceuticals Inc. said Tuesday that the Belgian health ministry has authorized the company to market the antiviral drug Virazole in aerosol form for the treatment of influenza A and B infections in infants and adults. The drug may be used to treat several thousand cases annually, said Jack Sholl, a spokesman for ICN, which makes pharmaceuticals, biotechnology research supplies and medical diagnostic products.
BUSINESS
June 2, 1994 | Anne Michaud, Times staff writer
SPI Turns to PR: SPI Pharmaceuticals in Costa Mesa said Wednesday it has hired public relations agency Edelman Medical Communications of New York to give its products higher visibility in the scientific community. In particular, SPI said, it wants to promote its leading drug, Virazole.
Los Angeles Times Articles
|